Definitive Contract 75N93019C00030

Award Date 7/31/19
Potential Completion Date 7/31/22
Potential Value $1.5M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92111, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed

This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective of the contract is to develop cytomegalovirus (CMV) IgG and IgM lateral flow assays required to support a large-scale CMV vaccination trial. Nanocomposix has prior experience providing lateral flow assay devices, gold nanoparticles, and research and development services for biomedical technologies such as HIV vaccines, tuberculosis diagnostics, and CMV assays under past contracts with the Department of Health and Human Services and Department of Defense. This contract is a Small Business Innovation Research (SBIR) Program Phase II action.

Generated 3/24/24, 3:42 AM